News Headlines Article

Health Reform in Limbo, Top Drug Lobbyist Quits
New York Times - David Kirkpatrick and Duff Wilson

Billy Tauzin, one of the highest paid lobbyists in Washington, is resigning as president of the pharmaceutical industry’s trade group amid internal disputes over its pact with the White House to trade political support for favorable terms in the proposed health care overhaul. As the industry’s top lobbyist, Mr. Tauzin brokered the deal last summer with the White House and Max Baucus, chairman of the Senate Finance Committee, to limit the drug industry’s total costs under the proposed health care overhaul to $80 billion over 10 years.